Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide - Novartis

Drug Profile

Octreotide - Novartis

Alternative Names: Octreotide acetate; Octreotide hydrochloride; Octreotide pamoate; Oncolar; Sandostatin LAR Depot; SMS 201995 ac; SMS 201995 pa; SMS 201995 pa LAR; SMS pa; SMS-201-995; SMS-995; SMS-995-AAA

Latest Information Update: 03 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Intestinal obstruction; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Phase II Diarrhoea
  • Discontinued Diabetic retinopathy; Polycystic liver disease; Prostate cancer; Thymoma

Most Recent Events

  • 19 Oct 2018 Efficacy and adverse events data from a phase II trial in Diarrhoea presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 05 Dec 2017 Novartis terminates a phase II trial in Diarrhoea (Prevention, Chemotherapy-induced) in United Kingdom, Italy, Czechia, Greece, France, Czech Republic, Russia, Poland, Hong Kong, and Israel due to futility by the Data Monitoring Committee (IM) (NCT02294786)
  • 03 Mar 2015 Discontinued - Phase-II/III for Polycystic liver disease, Prostate cancer and Thymoma in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top